Core Viewpoint - Ginkgo Bioworks (Shaoxing) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, aiming to go public on the main board [1] Company Overview - Ginkgo Bioworks is a leading precision medicine company in China, deeply integrating AI capabilities into various core aspects of the biomarker value chain [1] - The company has developed a multi-omics platform, combining foundational large models with intelligent AI, enabling a full-chain capability from the discovery and validation of multi-omics biomarkers and targets to product development and commercialization [1] Solutions Offered - The company provides three main solutions targeting hospitals, pharmaceutical and biotechnology companies, and medical research institutions: 1. Precision diagnostics 2. Drug development empowerment 3. Clinical research and translation [1] Innovation Framework - Ginkgo Bioworks is committed to accelerating the large-scale clinical application of AI-driven multi-omics technology through an innovative framework that synergizes multi-omics and AI [1] - The goal is to better serve the growing unmet medical needs of the vast patient population in China [1]

Core Viewpoint - GeneTech (Shaoxing) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, indicating its position as a leading precision medicine company in China that integrates AI capabilities into the biomarker value chain [1] Company Overview - GeneTech utilizes a self-developed multi-omics platform, combining foundational large models and intelligent AI to create a comprehensive capability from the discovery and validation of multi-omics biomarkers and targets to product development and commercialization [1] Solutions Offered - The company provides three main solutions targeting hospitals, pharmaceutical and biotechnology companies, and medical research institutions: 1. Precision Diagnosis 2. Drug Development Empowerment 3. Clinical Research and Translation [1]

Group 1 - The core viewpoint of the article is that Geneplus Technology (Shaoxing) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, indicating its intention to go public [1] - Geneplus is recognized as a leading precision medicine company in China, integrating AI capabilities deeply into the biomarker value chain [1] - The company has developed a comprehensive capability from biomarker and target discovery, validation, product development to commercialization based on its self-developed multi-omics platform [1] Group 2 - Geneplus offers three main solutions targeting hospitals, pharmaceutical and biotechnology companies, and medical research institutions: precision diagnosis, drug development empowerment, and clinical research and translation [1] - The company is backed by joint sponsors, including CCB International and Minmetals Capital, for its listing process [1] - The shares are priced at RMB 1.00 per H share, with additional fees for commissions and transaction costs outlined in the prospectus [1]